ADVFN - Advanced Financial Network.
HOME» NYSE » M » MRK Stock Price » MRK Stock News

Merck Share News

 Merck & Co., Stock Price
MRK Stock Price
 Merck & Co., Stock Chart
MRK Stock Chart
 Merck & Co., Stock News
MRK Stock News
 Merck & Co., Company Information
MRK Company Information
 Merck & Co., Stock Trades
MRK Stock Trades

Ligand: Glaxo Receives Priority Review for Eltrombopag's Supplemental NDA

By Victoria Stilwell Ligand Pharmaceuticals Inc. (LGND) said the U.S. Food and Drug Administration granted its partner, GlaxoSmithKline PLC (GSK), priority review of the supplemental new drug application for its eltrombopag drug, which treats thrombocytopenia in patients with chronic hepatitis C virus infection. Eltrombopag, known by the brand name Promacta in the U.S., is currently approved in 89 countries as a treatment for patients with chronic immune thrombocytopenia. Thrombocytopenia is a condition in which a patient's blood has a lower-than-normal number of platelets, allowing mild to serious bleeding to occur inside the body or underneath or from the skin. The drug is used to increase the number of cells that help the blood clot in order to decrease the risk of bleeding. Ligand is a biopharmaceutical company that aims to develop or acquire diverse, royalty-revenue-generating assets and couple them with a lean corporate cost structure. Ligand has also partnerships with companies including Merck & Co. (MRK), Pfizer Inc. (PFE) and Eli Lilly & Co. (LLY). Shares of Ligand closed Tuesday at $17.61 and were inactive in premarket trade. The stock is up 48% so far this year. Write to Victoria Stilwell at Victoria.Stilwell@dowjones.com Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stock News for Merck (MRK)
DateTimeHeadline
07/31/201519:27:51WHO Says Ebola Vaccine Effective in African Trial -- Update
07/31/201515:16:17WHO Says Ebola Vaccine Effective in African Trial -- Update
07/31/201509:00:04WHO Says Ebola Vaccine Effective in African Trial
07/31/201509:00:03WHO Says Ebola Vaccine Effective in African Trial -- Update
07/31/201508:47:49WHO Says Ebola Vaccine Effective in African Trial
07/31/201508:10:00In Interim Results from Phase 3 Study, Merck’s Investigational E...
07/30/201508:00:00Celebrity Chef Leticia Moreinos Schwartz, Merck and the American...
07/28/201517:00:35Gilead Sales Soar on Hepatitis Drugs
07/28/201516:34:36Current Report Filing (8-k)
07/28/201516:15:00Pamela J. Craig and Dr. Paul B. Rothman Elected to Merck Board...
07/28/201512:26:16Merck Earnings Hurt by Arthritis Drug Knockoffs
07/28/201508:23:48Merck Reports Better-Than-Seen Profits, Buy Of Cancer Drug Maker--Update
07/28/201508:20:10Merck Earnings Top Views Amid Cost Cuts
07/28/201508:12:33Merck Reports Better-Than-Seen Profits, Buy Of Cancer Drug Maker
07/28/201507:07:41Current Report Filing (8-k)
07/28/201507:00:00Merck Announces Second-Quarter 2015 Financial Results
07/28/201506:45:00Merck Enhances Immuno-Oncology Portfolio with Acquisition of...
07/28/201506:30:00Merck Announces U.S. Food & Drug Administration Acceptance of...
07/27/201508:30:00Merck Receives Positive CHMP Opinion for Investigational Antibiotic...
07/24/201516:14:52Current Report Filing (8-k)

Merck and other New York Stock Exchange stock quotes are delayed by at least 20 minutes.
All other stock price data is delayed by at least 15 minutes unless otherwise stated.
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations

ADVFNADVFN ItalyADVFN GermanyADVFN FranceADVFN BrazilADVFN JapanADVFN UKADVFN US noad